References

  1. Syed-Abdul, S., et al., Superbug demands organizational change of the healthcare system. J Pharmacol Pharmacother, 2011. 2(2): p. 132-3.

  2. Anzaldi, L.L. and E.P. Skaar, The evolution of a superbug: how Staphylococcus aureus overcomes its unique susceptibility to polyamines. Mol Microbiol, 2011. 82(1): p. 1-3.

  3. Arias, C.A. and B.E. Murray, Antibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge. New England Journal of Medicine, 2009. 360(5): p. 439-443.

  4. Bush, K., et al., Tackling antibiotic resistance. Nature Reviews Microbiology, 2011. 9(12): p. 894-896.

  5. Mangili, A., et al., Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis, 2005. 40(7): p. 1058-60.

  6. Lehr, P., Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products, B. Research, Editor 2011.

  7. Prevention, C.f.D.C.a., Antibiotic Resistance Threats in the United States, 2013, U.D.o.H.a.H. Services, Editor 2013.

  8. Economic Aspects of Antibiotic Resistance, in ReAct facts2008.

  9. Tamma, P.D., S.E. Cosgrove, and L.L. Maragakis, Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev, 2012. 25(3): p. 450-70.

  10. Carmeli, Y., et al., Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med, 1999. 159(10): p. 1127-32.

  11. Govan, J.R. and V. Deretic, Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev, 1996. 60(3): p. 539-74.

  12. Parkins, M.D., J.C. Rendall, and J.S. Elborn, Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest, 2012. 141(2): p. 485-93.

  13. Gibson, R.L., J.L. Burns, and B.W. Ramsey, Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med, 2003. 168(8): p. 918-51.

  14. Cystic Fibrosis Foundation Patient Registry Annual Data Report to the Center Directors 2009. 2010.

  15. Pace, J.R., M; Finch, RG, Biofilms, infection, and antimicrobial therapy. 2005, Boca Raton, FL: Taylor & Francis.

  16. Lambert, P.A., Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J R Soc Med, 2002. 95 Suppl 41: p. 22-6.

  17. Rogers, S.A., et al., Synergistic effects between conventional antibiotics and 2-aminoimidazole-derived antibiofilm agents. Antimicrob Agents Chemother, 2010. 54(5): p. 2112-8.

  18. Rogers, S.A. and C. Melander, Construction and screening of a 2-aminoimidazole library identifies a small molecule capable of inhibiting and dispersing bacterial biofilms across order, class, and phylum. Angew Chem Int Ed Engl, 2008. 47(28): p. 5229-31.

  19. Richards, J.J., T.E. Ballard, and C. Melander, Inhibition and Dispersion of Pseudomonas aeruginosa Biofilms with Reverse Amide 2-Aminoimidazole Oroidin Analogues. Organic and Biomolecular Chemistry, 2008. 6(8): p. 1356-1363.

  20. Melander, C., Cavanagh, J., Huigens, R., Ballard, T., Richards, J., Inhibition of bacterial biofilms with imidazole derivatives, 2011, North Carolina State University: United States.

  21. Lazarus, G.S., et al., Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol, 1994. 130(4): p. 489-93.

  22. Sen, C.K., et al., Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen, 2009. 17(6): p. 763-71.

  23. Kuehn, B.M., Chronic wound care guidelines issued. Jama-Journal of the American Medical Association, 2007. 297(9): p. 938-939.

  24. Mustoe, T.A., K. O’Shaughnessy, and O. Kloeters, Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis. Plast Reconstr Surg, 2006. 117(7 Suppl): p. 35S-41S.

  25. Ammons, M.C.B., et al., In vitro susceptibility of established biofilms composed of a clinical wound isolate of Pseudomonas aeruginosa treated with lactoferrin and xylitol. International Journal of Antimicrobial Agents, 2009. 33(3): p. 230-236.

  26. Black, C.E. and J.W. Costerton, Current concepts regarding the effect of wound microbial ecology and biofilms on wound healing. Surg Clin North Am, 2010. 90(6): p. 1147-60.

  27. Ammons, M.C., Anti-biofilm strategies and the need for innovations in wound care. Recent Pat Antiinfect Drug Discov, 2010. 5(1): p. 10-7.

  28. Bunders, C.A., J.J. Richards, and C. Melander, Identification of aryl 2-aminoimidazoles as biofilm inhibitors in Gram-negative bacteria. Bioorg Med Chem Lett, 2010. 20(12): p. 3797-800.

  29. Lindsey, E.A., et al., 2-Aminopyrimidine as a novel scaffold for biofilm modulation. Org Biomol Chem, 2012. 10(13): p. 2552-61.

  30. Rogers, S.A., et al., Synthesis and biological evaluation of 2-aminoimidazole/carbamate hybrid anti-biofilm and anti-microbial agents. Bioorg Med Chem Lett, 2011. 21(4): p. 1257-60.